Patents by Inventor Ichie Kato
Ichie Kato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6476039Abstract: The ophthalmic composition of this invention are used for treatment of diabetic corneal lesion and/or for treatment of deteriorated corneal esthesia, which comprises, as an active ingredient, a compound represented by the general formula (I): wherein A and B are independently lower alkylene, X, Y, and Z are independently halogen, or a pharmacologically acceptable salt thereof. In addition, the ophthalmic composition of this invention are used for treatment of non-diabetic corneal lesion, for treatment of dry eye syndrome, and/or for treatment of hypolacrimation which comprises, as an active ingredient, an aldose reductase inhibitor. The ophthalmic compositions of this invention are effective for treatment of at least one disease selected among corneal lesion, deteriorated corneal esthesia, dry eye syndrome, and hypolacrimation.Type: GrantFiled: April 29, 2002Date of Patent: November 5, 2002Assignee: R-Tech Ueno, Ltd.Inventors: Ryuji Ueno, Ichie Kato
-
Publication number: 20020161015Abstract: The ophthalmic composition of this invention are used for treatment of diabetic corneal lesion and/or for treatment of deteriorated corneal esthesia, which comprises, as an active ingredient, a compound represented by the general formula (I): 1Type: ApplicationFiled: April 29, 2002Publication date: October 31, 2002Applicant: R-TECH UENO, LTD.Inventors: Ryuji Ueno, Ichie Kato
-
Patent number: 6403598Abstract: The ophthalmic composition of this invention are used for treatment of diabetic corneal lesion and/or for treatment of deteriorated corneal esthesia, which comprises, as an active ingredient, a compound represented by the general formula (I): wherein A and B are independently lower alkylene, X, Y, and Z are independently halogen, or a pharmacologically acceptable salt thereof. In addition, the ophthalmic composition of this invention are used for treatment of non-diabetic corneal lesion, for treatment of dry eye syndrome, and/or for treatment of hypolacrimation which comprises, as an active ingredient, an aldose reductase inhibitor. The ophthalmic compositions of this invention are effective for treatment of at least one disease selected among corneal lesion, deteriorated corneal esthesia, dry eye syndrome, and hypolacrimation.Type: GrantFiled: February 10, 2000Date of Patent: June 11, 2002Assignee: R-Tech Ueno, Ltd.Inventors: Ryuji Ueno, Ichie Kato
-
Patent number: 6339088Abstract: A composition for treatment of external secretion disorders except hypolacrimation which comprises, as an active ingredient, an aldose reductase inhibitor. The composition is effective in at least one of diseases selected from hyposalivation and dry mouth syndrome.Type: GrantFiled: October 18, 2000Date of Patent: January 15, 2002Assignee: R-Tech Ueno. Ltd.Inventors: Ryuji Ueno, Ichie Kato
-
Patent number: 6265440Abstract: The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarkably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.Type: GrantFiled: May 6, 1998Date of Patent: July 24, 2001Assignee: R-Tech Ueno, Ltd.Inventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5886034Abstract: The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13, 14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.Type: GrantFiled: March 10, 1995Date of Patent: March 23, 1999Assignee: Kabushiki Kaisha Ueno Seiyaku KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5534547Abstract: The present invention provides novel prostaglandins D, that is, 13,14-dihydro-15-keto-PGDs, whieh have an excellent sedative and sleep-inducing activity, and so they are useful for tranquilizer and/or soporifics.Type: GrantFiled: September 23, 1994Date of Patent: July 9, 1996Assignee: Kabushiki Kaisha Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5428062Abstract: The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E.Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.Type: GrantFiled: April 28, 1993Date of Patent: June 27, 1995Assignee: K.K. Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5380709Abstract: The novel 13, 14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto prostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13, 14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.Type: GrantFiled: April 28, 1993Date of Patent: January 10, 1995Assignee: K.K. Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5284858Abstract: The novel 13, 14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-ketoprostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E.Therefore, the novel 13, 14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.Type: GrantFiled: August 6, 1992Date of Patent: February 8, 1994Assignee: Kabushiki Kaisha Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5225439Abstract: The novel 13, 14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13, 14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.Type: GrantFiled: April 5, 1991Date of Patent: July 6, 1993Assignee: K.K. Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5166174Abstract: The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.Type: GrantFiled: May 13, 1991Date of Patent: November 24, 1992Assignee: K.K. Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5137915Abstract: The present invention provides novel prostaglandins D, that is, 13,14-dihydro-15-keto-PGDs, which have an excellent sedative and sleep-inducing activity, and so they are useful for tranquilizer and/or soporifics.Type: GrantFiled: June 13, 1991Date of Patent: August 11, 1992Assignee: K.K. Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 5073569Abstract: The present invention provides novel prostaglandins D, that is, 13,14-dihydro-15-keto-PGDs, which have an excellent sedative and sleep-inducing activity, and so they are useful for tranquilizer and/or soporifics.Type: GrantFiled: September 6, 1989Date of Patent: December 17, 1991Assignee: K.K. Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Ichie Kato, Tomio Oda
-
Patent number: 4868203Abstract: A bacterial substance UFC-N11 of the formula: ##STR1##Type: GrantFiled: May 22, 1987Date of Patent: September 19, 1989Assignee: Kabushikikaisha Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Ryuji Ueno, Hiroshi Kita, Ichie Kato, Akihiko Tabata, Takashi Hironaka